MEASURES TO IMPROVE PRECLINICAL RESEARCH CONDUCTED TO IMPROVE THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

Authors

  • Sokhib Zamon o'g'li Rashidov Department of the pharmacology of the Tashkent state medical university Author
  • Temurmalik Ulug’bek o’g’li G’aybullaev , Zukhriddin Alisher oʻgʻli Oʻrishboev Tashkent state medical university Author

DOI:

https://doi.org/10.5281/zenodo.20376393

Keywords:

Health system, stroke, ischemic heart disease, cardiovascular disease, care systems, preventive drug therapy.

Abstract

Globally, cardiovascular disease (CVD) continues to be the primary cause of morbidity and mortality. The worldwide burden of CVD is still high despite tremendous advancements in diagnosis and treatment, highlighting the critical need for more thorough and efficient preventative measures. The purpose of this narrative summary is to assess the existing cornerstones of cardiovascular prevention critically, point out areas where current methods fall short, and suggest possible future paths. The majority of deaths worldwide are caused by cardiovascular disease (CVD), which primarily affects low- and middle-income countries (LMIC). Globally, primary and secondary prevention of CVD is not at its best, but in LMICs, the gaps between evidence and practice are considerably more noticeable. Optimal primary and secondary prevention cannot be implemented due to obstacles at the patient, healthcare practitioner, and health system levels. To develop successful methods to close the observed evidence-practice gaps, it is essential to identify the specific obstacles that occur in settings with limited resources. Additionally, the greatest improvements in mortality reduction will come from focusing on the modifiable factors—such as tobacco use, hypertension, and secondary prevention for CVD—that contribute most significantly to the worldwide burden of CVD. We examine a few innovative, resource-efficient approaches to lower premature mortality from CVD, such as: (1) efficient tobacco control measures; (2) the use of simplified screening and management algorithms for individuals with or at risk of CVD; (3) expanding the availability and affordability of simplified and cost-effective treatment regimens, such as combination CVD preventive drug therapy; and (4) streamlining health care delivery through task-sharing (non-physician health workers) and improving self-management (treatment supporters). Significant decreases in CVD and associated mortality will result from the development and implementation of care systems that overcome the aforementioned obstacles.

References

1.Combating cardiovascular disease disparities: the potential role of artificial intelligence. Orakwue CJ, Tajrishi FZ, Gistand CM, Feng H, Ferdinand KC. Am J Prev Cardiol. 2025;22:100954. doi: 10.1016/j.ajpc.2025.100954.

2.Dores H, Ferreira Santos J, Gil V, Gonçalves PdA. Cardiovascular Prevention: Current Gaps and Future Directions. Diagnostics. 2026; 16(1):16. https://doi.org/10.3390/diagnostics16010016

3.Schwalm JD, McKee M, Huffman MD, Yusuf S. Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation. 2016 Feb 23;133(8):742-55. doi: 10.1161/CIRCULATIONAHA.115.008721.

4.Artificial intelligence in the risk prediction models of cardiovascular disease and development of an independent validation screening tool: a systematic review. Cai Y, Cai YQ, Tang LY, et al. BMC Med. 2024;22:56. doi: 10.1186/s12916-024-03273-7.

5.Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.

6.Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761

7.Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670

8.Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01

9.Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07

10.Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06

11.Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863

12.Wearable devices for physical monitoring of heart: a review. Prieto-Avalos G, Cruz-Ramos NA, Alor-Hernández G, Sánchez-Cervantes JL, Rodríguez-Mazahua L, Guarneros-Nolasco LR. Biosensors (Basel) 2022;12 doi: 10.3390/bios12050292.

13.The global burden of cardiovascular diseases and risk: a compass for future health. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. J Am Coll Cardiol. 2022;80:2361–2371. doi: 10.1016/j.jacc.2022.11.005.

14.Mesenchymal stromal cell therapy (REGENACIP(®)), a promising treatment option in chronic limb threatening ischemia - a narrative review. Desai S, Sharma D, Srinivas R, et al. Stem Cell Res Ther. 2024;15:352. doi: 10.1186/s13287-024-03957-0.

15.Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820

16.Sokhib Rashidov Zamon oʻgʻli, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856

17.Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434

18.Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577

19.Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.

20.Sokhib Rashidov Zamon oʻgʻli, Nilufar Ergasheva Agʼzamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065

21.Sokhib Rashidov Zamon oʻgʻli, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Poʻlatjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141

22.Sokhib Rashidov Zamon oʻgʻli, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142

23.Sokhib Rashidov Zamon oʻgʻli, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.

24.The heart of the world. Di Cesare M, Perel P, Taylor S, et al. Glob Heart. 2024;19:11. doi: 10.5334/gh.1288.

25.Sokhib Rashidov Zamon oʻgʻli, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qoʻshbekova Roʻzimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857

Downloads

Published

2026-05-25